The global erythropoietin stimulating agents market size is anticipated to expand at a significant CAGR during the forecast period, 2021-2028. The growth of the market is attributed to increasing incidence of kidney diseases, chemotherapy, and major surgeries.
Erythropoietin (EPO) is a hormone that is produced mainly in kidneys which stimulates production and maintenance of red blood cells. It is a protein coding gene. EPO stimulating agents (ESAs) are mainly used often for people with long term kidney disease and anemia. Normal range of EPO is between 2.6 and 18.5 milliunits per milliliter (mU/mL).
The acute kidney injury (AKI) and anemia patients avoid EPO stimulating agents (ESAs, as these patients are unsuitable to effective response to ESAs due to the inflammation. Thus, the risks associated with ESA treatments are expected to outweigh the potential benefits.
Market Trends, Drivers, Restraints and Opportunities
- Increasing number of patients suffering from anemia and increasing application in HIV infections are expected to drive the market growth in the coming years.
- Rising prevalence of heart diseases and high blood pressure are estimated to spur the market growth in the coming years.
- High price of treatments such as chemotherapy and kidney surgery, namely nephrectomy, can hinder the market growth.
- Increasing side effects of ESAs is estimated to restrain the market growth.
- Growing focus on value-based medicine is anticipated to create significant opportunities for the market players.
Scope of the Report
The report on the global erythropoietin stimulating agents market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
| Attributes | Details |
| Report Title | Erythropoietin Stimulating Agents Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
| Base Year | 2020 |
| Historic Data | 2018–2019 |
| Forecast Period | 2021–2028 |
| Segmentation | Types (Epoetin Alfa, Epoetin Beta, Darbepoetin Alfa, and Others) and Applications (Cancer, Renal Disorders, Anti-retroviral Treatment, Neural Diseases, and Others) |
| Regional Scope | Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
| Report Coverage | Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
| Key Players Covered in the Report | Johnson and Johnson; Pfizer Inc.; Amgen Inc.; Thermo Fisher Scientific; F. Hoffmann La Roche Ltd. |
Erythropoietin Stimulating Agents Market Segment Insights
Darbepoetin alfa segment to hold a significant market share
On the basis of types, the market is divided into epoetin alfa, epoetin beta, darbepoetin alfa, and others. The epoetin alfa segment is anticipated to hold a key share of the market in the coming years due to increasing utilization for treatment of anemia, which is caused by chemotherapy. However, the darbepoetin alfa segment is anticipated to expand at a rapid pace during the forecast period due to increasing use for the treatment of chronic kidney diseases.
Anti-retroviral treatment segment is expected to grow at a rapid pace
Based on application, the market is divided into cancer, renal disorders, anti-retroviral treatment, neural diseases, and others. The cancer segment is expected to represent a key share of the market in the upcoming years due to reduced pain and other problem caused by tumor and to kill cancer cells that have spread to other parts of the body. On the other hand, the anti-retroviral treatment segment is anticipated to expand at a rapid pace during the forecast period to prevent HIV virus from multiplying and destroying infection fighting cells.
North America is estimated to account a major market share
In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is expected to constitute a key share of the market in the upcoming years due to increasing number of uncontrolled high blood pressure patients in the US. The market in Asia Pacific is expected to grow at a robust rate during the forecast period owing to rapid development in healthcare infrastructure such as India and China.
Segments
Segments Covered in the Report
The global erythropoietin stimulating agents market has been segmented on the basis of
Types
- Epoetin Alfa
- Epoetin Beta
- Darbepoetin Alfa
- Others
Applications
- Cancer
- Renal Disorders
- Anti-retroviral Treatment
- Neural Diseases
- Others
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- Johnson and Johnson
- Pfizer Inc.
- Amgen Inc.
- Thermo Fisher Scientific
- F. Hoffmann La Roche Ltd.
Competitive Landscape
Key players competing in the erythropoietin stimulating agents market includes Johnson and Johnson; Pfizer Inc.; Amgen Inc.; Thermo Fisher Scientific; F. Hoffmann La Roche Ltd.
Some of these players are engaging in business strategies such as mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to enhance their market share.
In February 2020, Samsung Medical Center studied on the efficacy of intravenous iron injection, Ferinject, in cancer patients with anemia.
Request For Customization
Enquiry Before Buying
Speak With Analyst
